Cancer clinical trials in the region Auvergne-Rhône-Alpes

505 currently recruiting clinical trials
Region Auvergne-Rhône-Alpes
Phase 2 Breast cancer Prostate cancer Colon cancer Rectal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer Thyroid and adrenal gland cancer #NCT03175224 #2024-514542-37-00
Cohortes C, D
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
MET
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded genetic anomalies
BRAF EGFR KRAS G12C KRAS non G12C NTRK-1/2/3 RET ALK ROS-1
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive Targeted therapy
5 recruiting sites
Apollomics
Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer Thyroid and adrenal gland cancer Brain tumors / Central nervous system tumors #NCT03175224 #2024-514542-37-00
Cohorte F
Required number of previous lines of therapy
1 2 3 or more
Excluded genetic anomalies
ALK BRAF EGFR KRAS G12C KRAS non G12C MET NTRK-1/2/3 RET ROS-1
Excluded previous treatments
Systemic Treatment-Naive
5 recruiting sites
Apollomics
Phase 2 Brain tumors / Central nervous system tumors #NCT03175224 #2024-514542-37-00
Cohorte E
Required genetic anomalies
MET
Required number of previous lines of therapy
1 2 3 or more
Excluded genetic anomalies
BRAF EGFR NTRK-1/2/3 ALK KRAS G12C KRAS non G12C RET ROS-1
Excluded previous treatments
Systemic Treatment-Naive
5 recruiting sites
Apollomics
Phase 2 Endometrial cancer #NCT05548296 #2025-524542-10-00
Bras 3 et 4
Required histologic sub types
Serous adenocarcinoma
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
1 2
Required previous treatments at advanced or metastatic stage
Immunotherapy Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
4 recruiting sites
Acrivon Therapeutics
Phase 2 Ovarian / Fallopian tubes / Peritoneum cancer #NCT06906341 #2024-517432-21-00
Bras A (Cancer de l'ovaire résistant au platine)
Required histologic types
Epithelial ovarian cancer Fallopian tube cancer Primary peritoneal cancer (PPC)
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Required platino resistance
Recurrence within 6 months after platinum-based tr...
Required previous treatments at localized stage
Chemotherapy
Required previous treatments at advanced or metastatic stage
Chemotherapy
Excluded previous treatments at localized stage
Systemic Treatment-Naive
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
6 recruiting sites
Corcept Therapeutics
Phase 2 Lung cancer #NCT07234058 #2024-519208-29-00
Required histologic types
Mesothelium
Required disease stage
Locally Advanced
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded previous treatments at advanced or metastatic stage
Immunotherapy Chemotherapy
4 recruiting sites
Intergroupe Francophone de Cancérologie Thoracique
Phase 2 Ovarian / Fallopian tubes / Peritoneum cancer #NCT06906341 #2024-517432-21-00
Bras B (Cancer de l'ovaire sensible au platine post PARPI)
Required histologic types
Epithelial ovarian cancer Fallopian tube cancer Primary peritoneal cancer (PPC)
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Required platino resistance
Recurrence 6 months or more after platinum treatme...
Required previous treatments at localized stage
Chemotherapy Targeted therapy
Required previous treatments at advanced or metastatic stage
Chemotherapy Targeted therapy
Excluded previous treatments at localized stage
Systemic Treatment-Naive
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
6 recruiting sites
Corcept Therapeutics
Phase 2 Endometrial cancer #NCT06906341 #2024-517432-21-00
Bras C (Cancer de l'endomètre)
Required FIGO stages
Stage III Stage IV
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1 2
Required previous treatments at advanced or metastatic stage
Immunotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
6 recruiting sites
Corcept Therapeutics
Phase 2 Lung cancer #NCT07203053 #2025-522288-13-00
Required histologic types
SCLC (Small Cell Lung Cancer)
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Immunotherapy Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
1 recruiting site
ETOP IBCSG Partners Foundation
Phase 2 Chronic myeloid leukemia (CML) #NCT06514534 #2024-516049-38-00
Required disease stage
Chronic phase Accelerated phase
Required genetic anomalies
T315I
Required number of previous lines of therapy
1 2 3 or more
Required previous treatments
ATP pocket inhibitor
Excluded previous treatments
Systemic Treatment-Naive Allosteric inhibitor
7 recruiting sites
Novartis